Work to discover drugs for rare and immunological diseases recognised as part of Oxfordshire Business Awards
Oxford, UK, June 18 2022 – Its work in discovering medicines for rare and immunological diseases has earned OMass Therapeutics The Oxford Science Park Innovation Award 2022. Given as part of the Oxfordshire Business Awards, it recognises the company’s progress in generating a pipeline of small molecule therapeutics, discovered using its proprietary OdyssION™ platform. This is the fifth year that The Oxford Science Park, one of Europe’s leading locations for science and technology companies, has sponsored the Innovation Award.
In an Award open to companies in all sectors across the County, the judges were looking for an innovative product or process which had made progress over the past three years, driving corporate development in a significant way. Spun out of Oxford University, OMass has commercialised Professor Dame Carol Robinson’s breakthrough research in native mass spectrometry to develop OdyssION. The platform integrates novel biochemistry techniques, next-generation native mass spectrometry, and custom chemistry, to allow for the interrogation of protein interactions within its native ecosystem while avoiding the confounding complexity of the cell.
Rory Maw, CEO of The Oxford Science Park, said, ‘The judges were impressed by the exciting portfolio of drug candidates OMass Therapeutics has discovered, based on unique technology from the University of Oxford. They hold significant potential in the treatment of rare and immunological diseases, as recognised by investors in the company’s $100m Series B fundraising earlier this year.’
‘We are delighted to have been involved for the fifth year with the Oxfordshire Business Awards, which celebrate excellence across the County.’